Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Abstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA-...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-08-01
|
| Series: | Pediatric Rheumatology Online Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12969-021-00630-1 |
| _version_ | 1818645041210458112 |
|---|---|
| author | Sofia Lanz Gerald Seidel Andrea Skrabl-Baumgartner |
| author_facet | Sofia Lanz Gerald Seidel Andrea Skrabl-Baumgartner |
| author_sort | Sofia Lanz |
| collection | DOAJ |
| description | Abstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uveitis-related data, including intraocular inflammation, best-corrected visual acuity, corticosteroid-sparing potential, and ocular complications were evaluated at start of GLM treatment, at 1 month and 3 months, and every 3 months thereafter during GLM administration. We further investigated the association of response to GLM with primary and secondary failure of ADA treatment. Results Ten patients were studied, all female (17 affected eyes, mean age 14.3 + 6.7 yrs., mean follow-up 25.2 + 21.7 mos). Two patients were switched to GLM because of primary non-response to ADA. Eight were switched because of loss of response (LOR). In 5 of the latter LOR was associated with neutralizing anti-ADA-antibodies. Response to GLM was observed in all 8 patients with LOR, while the 2 patients with primary non-response to ADA also did not respond to GLM. Three of the 8 responders experienced LOR. At the end of follow-up 4 of the 5 remaining responders had achieved complete response. One had achieved partial response. Conclusion GLM is an efficacious therapeutic option in patients who experience LOR to ADA. Our data indicate that patients without primary response to ADA should be rather switched to a biologic agent with a different mode of action instead of further blocking the TNF-alpha pathway. |
| first_indexed | 2024-12-17T00:24:26Z |
| format | Article |
| id | doaj.art-046e18723441420db6e86f09f0df8907 |
| institution | Directory Open Access Journal |
| issn | 1546-0096 |
| language | English |
| last_indexed | 2024-12-17T00:24:26Z |
| publishDate | 2021-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Pediatric Rheumatology Online Journal |
| spelling | doaj.art-046e18723441420db6e86f09f0df89072022-12-21T22:10:30ZengBMCPediatric Rheumatology Online Journal1546-00962021-08-011911610.1186/s12969-021-00630-1Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to AdalimumabSofia Lanz0Gerald Seidel1Andrea Skrabl-Baumgartner2Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University GrazDepartment of Ophthalmology, Medical University GrazDivision of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University GrazAbstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uveitis-related data, including intraocular inflammation, best-corrected visual acuity, corticosteroid-sparing potential, and ocular complications were evaluated at start of GLM treatment, at 1 month and 3 months, and every 3 months thereafter during GLM administration. We further investigated the association of response to GLM with primary and secondary failure of ADA treatment. Results Ten patients were studied, all female (17 affected eyes, mean age 14.3 + 6.7 yrs., mean follow-up 25.2 + 21.7 mos). Two patients were switched to GLM because of primary non-response to ADA. Eight were switched because of loss of response (LOR). In 5 of the latter LOR was associated with neutralizing anti-ADA-antibodies. Response to GLM was observed in all 8 patients with LOR, while the 2 patients with primary non-response to ADA also did not respond to GLM. Three of the 8 responders experienced LOR. At the end of follow-up 4 of the 5 remaining responders had achieved complete response. One had achieved partial response. Conclusion GLM is an efficacious therapeutic option in patients who experience LOR to ADA. Our data indicate that patients without primary response to ADA should be rather switched to a biologic agent with a different mode of action instead of further blocking the TNF-alpha pathway.https://doi.org/10.1186/s12969-021-00630-1Juvenile idiopathic arthritisRefractory uveitisGolimumabAdalimumabTreatment failure |
| spellingShingle | Sofia Lanz Gerald Seidel Andrea Skrabl-Baumgartner Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab Pediatric Rheumatology Online Journal Juvenile idiopathic arthritis Refractory uveitis Golimumab Adalimumab Treatment failure |
| title | Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab |
| title_full | Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab |
| title_fullStr | Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab |
| title_full_unstemmed | Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab |
| title_short | Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab |
| title_sort | golimumab in juvenile idiopathic arthritis associated uveitis unresponsive to adalimumab |
| topic | Juvenile idiopathic arthritis Refractory uveitis Golimumab Adalimumab Treatment failure |
| url | https://doi.org/10.1186/s12969-021-00630-1 |
| work_keys_str_mv | AT sofialanz golimumabinjuvenileidiopathicarthritisassociateduveitisunresponsivetoadalimumab AT geraldseidel golimumabinjuvenileidiopathicarthritisassociateduveitisunresponsivetoadalimumab AT andreaskrablbaumgartner golimumabinjuvenileidiopathicarthritisassociateduveitisunresponsivetoadalimumab |